Literature DB >> 6590608

Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases.

F Lozada, S Silverman, C Migliorati.   

Abstract

Systemic glucocorticoids in the form of prednisone have been effective in reducing signs and symptoms in a variety of acute and chronic oral inflammatory diseases. In the 101 patients prospectively studied, the benefits from prednisone treatment far outweighed the adverse side effects, which occurred in 61 patients. However, none of the adverse side effects was severe enough to require cessation of the prednisone. The adverse effects, which could be minimized by reducing the dosage in most instances, were primarily related to treatment that persisted for more than two weeks. Fluid retention or bloating was the most common symptom, and insomnia was the chief side effect in those patients receiving short-term treatment (less than two weeks). Blood sugar, blood pressure, weight, and white blood cell counts were not meaningfully altered. Variables in patients' drug response and side effects precluded formulation of precise prednisone dosages that would allow predictive outcomes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6590608     DOI: 10.14219/jada.archive.1984.0349

Source DB:  PubMed          Journal:  J Am Dent Assoc        ISSN: 0002-8177            Impact factor:   3.634


  5 in total

1.  CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea--therapeutic difficulties and dilemmas.

Authors:  Charalampos Mermigkis; Demetrios Mermigkis; Georgios Varouchakis; Sophia Schiza
Journal:  Sleep Breath       Date:  2011-01-09       Impact factor: 2.816

Review 2.  Beyond Ockham's razor: redefining problem-solving in clinical sleep medicine using a "five-finger" approach.

Authors:  David E McCarty
Journal:  J Clin Sleep Med       Date:  2010-06-15       Impact factor: 4.062

3.  Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.

Authors:  N Bodor; W M Wu; T Murakami; S Engel
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

4.  Gaining the Upper Hand on Pulmonary Drug Delivery.

Authors:  Jean Tyrrell; Robert Tarran
Journal:  J Pharmacovigil       Date:  2014-03-01

5.  Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.

Authors:  Marco Frentsch; Alberto Sada Japp; Manuela Dingeldey; Nadine Matzmohr; Andreas Thiel; Friedrich Scheiflinger; Birgit M Reipert; Maurus de la Rosa
Journal:  J Thromb Haemost       Date:  2020-03-02       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.